13 August 2026
13 August 2026
Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.
Recommended changes to the US immunisation schedule by President Trump have been met with widespread retaliation.
The latest round brings the total capital raised by Remepy to $62m.
The authorisation is based on data from the HARMONi-6 multi-centre Phase III study that was conducted in China.
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
